Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Zynerba Pharma CS (ZYNE)

Zynerba Pharma CS (ZYNE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 183,984
  • Shares Outstanding, K 41,252
  • Annual Sales, $ 0 K
  • Annual Income, $ -51,340 K
  • 60-Month Beta 2.40
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.09
Trade ZYNE with:

Options Overview Details

View History
  • Implied Volatility 73.30%
  • Historical Volatility 50.17%
  • IV Percentile 1%
  • IV Rank 5.81%
  • IV High 284.24% on 03/05/21
  • IV Low 60.29% on 05/26/21
  • Put/Call Vol Ratio 0.02
  • Today's Volume 63
  • Volume Avg (30-Day) 181
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 3,796
  • Open Int (30-Day) 4,658

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.23
  • Number of Estimates 3
  • High Estimate -0.21
  • Low Estimate -0.25
  • Prior Year -0.31
  • Growth Rate Est. (year over year) +25.81%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.04 +10.40%
on 08/27/21
4.65 -4.08%
on 09/09/21
+0.26 (+6.19%)
since 08/24/21
3-Month
3.66 +21.73%
on 08/20/21
6.07 -26.52%
on 06/28/21
-1.31 (-22.70%)
since 06/24/21
52-Week
3.15 +41.59%
on 12/29/20
9.00 -50.44%
on 02/10/21
+1.23 (+38.08%)
since 09/24/20

Most Recent Stories

More News
Zynerba Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference

Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that...

ZYNE : 4.46 (-1.55%)
Zynerba Pharmaceuticals Presents Longer Term Tolerability and Efficacy Data of Zygel(TM) in Children and Adolescents with Autism Spectrum Disorder (ASD) at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021

Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today presented data...

ZYNE : 4.46 (-1.55%)
Zynerba Pharmaceuticals Announces Publication of Results of Phase 2 BELIEVE Open-Label Study of Zygel(TM) in Children and Adolescents with Developmental and Epileptic Encephalopathies (DEE) in JAMA Network Open

Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the...

ZYNE : 4.46 (-1.55%)
Zynerba Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Highlights

-- On track to initiate RECONNECT, a confirmatory pivotal trial of Zygel(TM) in patients with FXS, in the third quarter of 2021

ZYNE : 4.46 (-1.55%)
Zynerba: Q2 Earnings Snapshot

DEVON, Pa. (AP) _ Zynerba Pharmaceuticals Inc. (ZYNE) on Monday reported a loss of $10 million in its second quarter.

ZYNE : 4.46 (-1.55%)
CBD-Infused Products Market Is Expected to Exceed $210 Billion by 2028, at a CAGR of 45.6%

/PRNewswire/ -- Due to its healing properties, the demand for cannabidiol (CBD) for health and wellness purposes is high, which is the major factor driving the market growth. In addition, the rising acceptance...

OILFF : 0.1814 (-8.61%)
OILS.CN : 0.240 (-5.88%)
CBDHF : 0.2398 (-0.08%)
CBD-U.TO : 0.2350 (unch)
CWBHF : 2.0400 (-1.85%)
CWEB.TO : 2.59 (-1.15%)
YCBD : 2.04 (+0.49%)
ZYNE : 4.46 (-1.55%)
Zynerba Pharmaceuticals to Present at the Canaccord Genuity 41st Annual Growth Conference

Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that...

ZYNE : 4.46 (-1.55%)
Zynerba Pharmaceuticals to Present at the Ladenburg Thalmann Virtual Healthcare Conference

Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that...

ZYNE : 4.46 (-1.55%)
Zynerba Pharmaceuticals Announces Adjournment of Annual Meeting

- 49% of shares voted, quorum not established to hold annual meeting -

ZYNE : 4.46 (-1.55%)
Zynerba Pharmaceuticals Presents Sleep Data from Study of Zygel(TM) in Children and Adolescents with Both Developmental and Epileptic Encephalopathies (DEE) and Autism Spectrum Disorder (ASD) at the Associated Professional Sleep Societies SLEEP 2021 Annual Meeting

Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, presented a poster...

ZYNE : 4.46 (-1.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal...

See More

Key Turning Points

3rd Resistance Point 4.66
2nd Resistance Point 4.60
1st Resistance Point 4.53
Last Price 4.46
1st Support Level 4.40
2nd Support Level 4.35
3rd Support Level 4.28

See More

52-Week High 9.00
Fibonacci 61.8% 6.77
Fibonacci 50% 6.07
Fibonacci 38.2% 5.38
Last Price 4.46
52-Week Low 3.15

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar